Status:
COMPLETED
Predictors of Adherence to Orencia
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.
Eligibility Criteria
Inclusion
- Patients will be identified based on the presence of first infusion claim during study period for Orencia
- At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date
- Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below
- Patients with a minimum of 3 infusion claims for Orencia
- Only those patients will be included whose first 3 infusion claims occur within 84 days
Exclusion
- Patients less than 18 years of age at index date.
- One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period
- Patients who switch between biologics within their first three infusion claims
- Restarts, defined as those patients who go back on Orencia after a gap of 42 days
- Patients who are on other biologics at the same time as Orencia
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
422 Patients enrolled
Trial Details
Trial ID
NCT01136707
Start Date
December 1 2009
End Date
July 1 2010
Last Update
September 16 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.